Market research
0PT.F Prothena Corporation plc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 386M
- P/E ratio
- Not available
- Analyst target
- 75.75
- Dividend yield
- Not available
- Beta
- -0.33
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- IE00B91XRN20
- Market cap
- 386M
- P/E ratio
- Not available
- Analyst target
- 75.75
- Dividend yield
- Not available
- Beta
- -0.33
About
About Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 0PT.F discussion.
5 years, 5 months ago
Prothena Corporation plc is currently in a long term uptrend where the price is trading 144.0% above its 200 day moving average.
From a valuation standpoint, the stock is 12.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1152.3.
Prothena Corporation plc's total revenue rose by 40.6% to $360K since the same quarter in the previous year.
Its net income has dropped by 42.5% to $-31M since the same quarter in the previous year.
Finally, its free cash flow fell by 31.2% to $-19M since the same quarter in the previous year.
Based on the above factors, Prothena Corporation plc gets an overall score of 3/5.